Molecularly targeted therapies for acute myeloid leukemia Journal Article
| Author: | Stein, E. M. |
| Article Title: | Molecularly targeted therapies for acute myeloid leukemia |
| Abstract: | The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets. |
| Keywords: | unclassified drug; gene mutation; review; molecular genetics; antineoplastic agent; clinical practice; gene targeting; epigenetics; maximum tolerated dose; molecularly targeted therapy; isocitrate dehydrogenase 1; cd135 antigen; acute myeloid leukemia; clonal evolution; isocitrate dehydrogenase 2; quizartinib; human; pinometostat; venetoclax; crenolanib; gilteritinib; enasidenib; ag 120; birabresib |
| Journal Title: | Hematology-American Society of Hematology Education Program |
| Volume: | 2015 |
| ISSN: | 1520-4391 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-05 |
| Start Page: | 579 |
| End Page: | 583 |
| Language: | English |
| DOI: | 10.1182/asheducation-2015.1.579 |
| PROVIDER: | scopus |
| PUBMED: | 26637775 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 February 2018 -- Source: Scopus |
